Areteia Therapeutics Inc.

About Areteia Therapeutics Inc.

Areteia Therapeutics is a clinical stage biotechnology company dedicated to improving the lives of respiratory patients by developing the first potential oral drug for eosinophilic asthma, aiming to transform the patient journey in this condition.

Products & Services

Dexpramipexole:A first-in-class oral drug candidate that inhibits eosinophil maturation, currently in Phase III clinical trials for eosinophilic asthma with the goal of regulatory approval and commercialization.

Specialties

Eosinophilic Asthma Treatment Respiratory Disease Drug Development Oral Drug Innovation

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Series A T: - FT: Series A	A: 75000000 MR: - FA: $75 million FAN: 75000000	D: 2024-02-13 FD: 2024-02-13	10 investors

Series A Latest

2024-02-13

$75.0M

10 investors (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

J

Jorge Bartolome

Chief Executive Officer

P

Peter Wijngaard

Chief Development Officer

C

Calman Prussin

Chief Scientific Officer

M

Mark Kreston

Chief Commercial Officer

C

Christopher Courts

Chief Financial Officer

E

Eric Bradford

Chief Medical Officer

View 17 more team members with Pro

Unlock Full Team Directory

Recent News